** HK-listed shares of Laekna 2105.HK soar 37.2% to HK$14.54, highest since Jan. 11
** Stock set for biggest one-day pct rise since April 15
** Chinese biotech firm enters into agreement with Eli Lilly LLY.N to accelerate global clinical development of LAE102, used to treat obesity
** Under the deal, Lilly will fund and execute LAE102's phase I study in the U.S., while Laekna will retain the drug's global rights
** Hong Kong's healthcare index .HSCIH up 2.8%, while Hang Seng Index .HSI slips 0.1%
** Stock trims YTD losses to 32.3%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments